

**AMENDMENTS TO THE CLAIMS**

Claims 1-11 (cancelled).

Claim 12 (new). An isolated oligopeptide consisting of 12 amino acid residues and having a hydropathy profile in which the side chains of the amino acid residues 2 and 5 have positive hydropathy values, the side chains of amino acid residues 3, 4, 8 and 11 have negative hydropathy values, and the side chains of amino acid residues at positions 1, 6, 7, 9, 10 and 12 can have either positive or negative hydropathy values; the oligopeptide being capable of mediating cell permeability to substances that are to be transported into a cell when the oligopeptide is linked to the substance by a covalent or non-covalent linkage.

Claim 13 (new). A fusion protein comprising a polypeptide covalently linked to an oligopeptide of claim 12.

Claim 14 (new). The fusion protein of claim 13 wherein the polypeptide is selected from the group consisting of a structural polypeptide, a tumor necrosis factor, an interferon, an interleukin, a lymphokine, a growth factor, and a plasma polypeptide.

Claim 15 (new). The fusion protein of claim 13 wherein the polypeptide is a cytokine.

Claim 16 (new). The fusion protein of claim 13 wherein the polypeptide is a co-stimulatory molecule.

Claim 17 (new). The fusion protein of claim 13 wherein the polypeptide is a tumor-associated antigen.

Claim 18 (new). The fusion protein of claim 13 wherein the polypeptide is a peptide fragment of a viral coat.

Claim 19 (new). The fusion protein of claim 13 wherein the polypeptide is a hormone.

Claim 20 (new). The fusion protein of claim 13 wherein the polypeptide is a ribozyme.

Claim 21 (new). An isolated oligopeptide consisting of 12 amino acid residues and having a hydropathy profile in which the side chains of the amino acid residues 2, 5 and 9 have positive hydropathy values, the side chains of amino acid residues 3, 4, 8 and 11 have negative hydropathy values, and the side chains of amino acid residues at positions 1, 6, 7, 10 and 12 can have either positive or negative hydropathy values; the oligopeptide being capable of mediating

cell permeability to substances that are to be transported into a cell when the oligopeptide is linked to the substance by a covalent or non-covalent linkage.

Claim 22 (new). A fusion protein comprising a polypeptide covalently linked to an oligopeptide of claim 21.

Claim 23 (new). The fusion protein of claim 22 wherein the polypeptide is selected from the group consisting of a structural polypeptide, a tumor necrosis factor, an interferon, an interleukin, a lymphokine, a growth factor, and a plasma protein.

Claim 24 (new). The fusion protein of claim 22 wherein the polypeptide is a cytokine.

Claim 25 (new). The fusion protein of claim 22 wherein the polypeptide is a co-stimulatory molecule.

Claim 26 (new). The fusion protein of claim 22 wherein the polypeptide is a tumor-associated antigen.

Claim 27 (new). The fusion protein of claim 22 wherein the polypeptide is a peptide fragment of a viral coat.

Claim 28 (new). The fusion protein of claim 22 wherein the polypeptide is a hormone.

Claim 29 (new). The fusion protein of claim 22 wherein the polypeptide is a ribozyme.

Claim 30 (new). An isolated oligopeptide consisting of 12 amino acid residues and having an amino acid residue sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.

Claim 31 (new). A fusion protein comprising a polypeptide covalently linked to an oligopeptide of claim 30.

Claim 32 (new). The fusion protein of claim 31 wherein the polypeptide is selected from the group consisting of a structural polypeptide, a tumor necrosis factor, an interferon, an interleukin, a lymphokine, a growth factor, and a plasma protein.

Claim 33 (new). The fusion protein of claim 31 wherein the polypeptide is a cytokine.

Claim 34 (new). The fusion protein of claim 31 wherein the polypeptide is a co-stimulatory molecule.

Claim 35 (new). The fusion protein of claim 31 wherein the polypeptide is a tumor-associated antigen.

Claim 36 (new). The fusion protein of claim 31 wherein the polypeptide is a peptide fragment of a viral coat.

Claim 37 (new). The fusion protein of claim 31 wherein the polypeptide is a hormone.

Claim 38 (new). The fusion protein of claim 31 wherein the polypeptide is a ribozyme.